Interchangeability, Switching and Substitution of Biotherapeutics: Clinical Issues and Challenges
|
|
- James Daniel
- 6 years ago
- Views:
Transcription
1 Interchangeability, Switching and Substitution of Biotherapeutics: Clinical Issues and Challenges Dr. Freddy José Faccin Lazo, M.D. Global Biotherapeutics Head Global Medical Affairs Abbvie
2 Overview Introduction and Definitions Analytical Considerations Clinical Considerations The Immunogenicity Switching Challenge Clinical Evidence on Non-Medical Switching: A Review Pharmacovigilance and Patient Management In a World With Multiple Biosimilars Conclusions
3 Overview Introduction and Definitions Analytical Considerations Clinical Considerations The Immunogenicity Switching Challenge Clinical Evidence on Non-Medical Switching: A Review Pharmacovigilance and Patient Management In a World With Multiple Biosimilars Conclusions
4 Treating patients with Biotherapeutics: Definitions US FDA: An interchangeable biologic product, in addition to meeting the biosimilarity standard, is one that is expected to produce the same clinical result as the reference product in any given patient 1 Interchangeability EU: The medical practice of changing one medicine for another that is expected to achieve the same clinical effect in a given clinical setting and in any patient 2 Regulatory term Transitioning/switching Physician-controlled action: single transition of patients from a reference product to a biosimilar 2 Substitution Pharmacist action: dispensing one medicine for another equivalent and interchangeable medicine at the pharmacy level without consulting the prescribing physician 2 1. FDA Information for consumers (biosimilars). Available at: milars/ucm htm; 2. European Commission. Consensus Information Paper What you need to know about Biosimilar Medicinal Products, 2013
5 Medically relevant switching TNF, tumor necrosis factor Evidence-based recommendation Patients treated with biologic therapy, who have an inadequate response or an intolerable AE, should be switched to a different biologic agent for clinical reasons Singh et al. Arthritis Rheumatol 2016;68:1 26; 2. Smolen et al. Ann Rheum Dis 2014;73: ; 3. Dignass et al. J Crohns Colitis 2010;4:28 62;
6 Non-medical switching (NMS) What is NMS? Switching of biologics among patients with well-tolerated, adequate therapy 1 3 What motivates NMS? Potential for cost-savings and/or procurement policies 1 4 Patient preference 1,2 What types of NMS occur? Across different agents from the same class 2,6 From a reference product to its biosimilar or vice versa 1. Rubin et al. ECCO 2015, Barcelona, P354; 2. Gibofsky et al. AMCP 2015, San Diego, Poster; 3. Liu Y et al. ISPOR 2015, Philadelphia, PHS26; 4. Morgan et al. Open Medicine 2009;3:131 9; 5. Declerck. GaBi J 2012;1:13 6; 6. Van Assche et al. Gut 2012;61:229 34
7 Overview Introduction and Definitions Analytical Considerations Clinical Considerations The Immunogenicity Switching Challenge Clinical Evidence on Non-Medical Switching: A Review Pharmacovigilance and Patient Management In a World With Multiple Biosimilars Conclusions
8 Biosimilar Development: What Can Be Minimized With Acceptable Risk? 1. FDA Guidance for Industry. Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product. HHS FDA/CDER/CBER, Feb 2012; 2. EMA CHMP Guideline on similar biological medicinal products, 30 Oct 2005; 3. Health Canada: Guideline for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics, March 2010; 4. WHO Guidelines on Evaluation of Similar Biotherapeutic Products, 2009
9 Aggregate Analysis Enables the Degree of Similarity to be Assessed 1,2 Tier 1: Statistical equivalence Tier 2: Quantitative numerical comparison Tier 3: Qualitative comparative assessment Quality attribute Criticality Relevant for Amino acid sequence Very high Efficacy, safety, immunogenicity Potency Very high Efficacy, safety Target binding Very high Efficacy, safety Protein concentration Very high Efficacy Subvisible particles High Immunogenicity Oxidised variants High Efficacy Higher order structure High molecular weight variants/aggregates High High Truncated variants Low None Norleucine Very low None Deamidation Very low None Efficacy, immunogenicity Immunogenicity 1. Adapted from: Kozlowski. FDA; European Generic Medicines Association Biosimilar Medicines - International Symposium London, UK, April 26, 2013; 2. FDA Oncologic Drugs Advisory Committee Meeting. ZARXIO (filgrastim) Advisory Committee Briefing Materials. January 7, 2015
10 Biosimilarity Index to Quantify Similarity: Medical Community The International Psoriasis Council suggests guidelines for standardization of pre-clinical assessments of emerging biosimilars through the development of a biosimilar index 1 1. Blauvelt A et al. British J Derm Oct 2015; doi: /bjd.14267
11 Mechanisms of Action of TNF inhibitors in Different Pathogenic Conditions Do we fully understand how biologic therapies exert their effects? 1-5 Binding of soluble TNF Avidity, affinity Binding to membrane-tnf Apoptosis Reverse signaling? Binding to Fc receptors Part of mode of action Elimination, recycling (half-life) Other(s)? 1. Miletich et al. mabs 2011;3: ; 2. Tracey et al. Pharmacol Ther 2008;117: ; 3. Vos et al. Inflamm Bowel Dis 2012;18: ; 4. Vos et al. Gastroenterology 2011;140: ; 5. Kuo & Aveson. mabs 2011;3: ; 6. Lee et al. AAPS 2014;16:22 26
12 Aggregate Analysis Enables the Degree of Similarity to be Assessed 1,2 Tier 1: Statistical equivalence Tier 2: Quantitative numerical comparison Tier 3: Qualitative comparative assessment Quality attribute Criticality Relevant for Amino acid sequence Very high Efficacy, safety, immunogenicity Potency Very high Efficacy, safety Target binding Very high Efficacy, safety Protein concentration Very high Efficacy Subvisible particles High Immunogenicity Oxidised variants High Efficacy Higher order structure High molecular weight variants/aggregates High High Truncated variants Low None Norleucine Very low None Deamidation Very low None Efficacy, immunogenicity Immunogenicity 1. Adapted from: Kozlowski. FDA; European Generic Medicines Association Biosimilar Medicines - International Symposium London, UK, April 26, 2013; 2. FDA Oncologic Drugs Advisory Committee Meeting. ZARXIO (filgrastim) Advisory Committee Briefing Materials. January 7, 2015
13 Overview Introduction and Definitions Analytical Considerations Clinical Considerations The Immunogenicity Switching Challenge Clinical Evidence on Non-Medical Switching: A Review Pharmacovigilance and Patient Management In a World With Multiple Biosimilars Conclusions
14 What is the Primary Concern? Immunogenicity Protein or Carbohydrate Exposure Immune Tolerance 4 Prevention of an immune response against a particular antigen Desired State: Immune Equilibrium & Stability of Response New Tolerance Equilibrium Modification of Protein or Carbohydrate Potential for Immunogenicity 1. Change to different drug 2. Drug Modification Primary loss of response Secondary loss of response Type-I hypersensitivity Type-III hypersensitivity 1. Chamberlain P.D., Biosimilars, 2014: 23-43; 2.Shankar et al. AAPS 2014;16:658 73; 3. Scott B et al, The journal of Clinical Pharmacology DOI:I 002/jcph.339; 4. National Inst. Allergy and Infect. Dis Accessed 3/22/
15 Mechanisms to Evaluate Clinical Switching 1 Reference drug Biosimilar Reference drug Biosimilar Reference drug Biosimilar Transition study Substitution study (single switch) Interchangeability study (multiple switches) demonstration of interchangeability should require testing of repeated switches between the reference product and the biosimilar Drug switching takes place when a patient is transitioned from one biopharmaceutical to another or from a reference biopharmaceutical to its biosimilar Figure: Study design to compare the efficacy of reference drugs and biosimilars. Switching, as has been carried out in clinical trials of some biosimilars, is compared with substitution involving single or multiple switches, as potential study designs to support the FDA designation of interchangeability. Switch studies are not required for approval by the EMA A switch study demonstrating no loss of efficacy nor increase in risk would support the transition under consideration 1. Dörner & Kay. Nat Rev Rheumatol 2015; doi: /nrrheum [Epub ahead of print]
16 Induction of the Immune Response According to the Prime-Boost Effect Persistent presence of an antigen induces an initial immune response followed by tolerance 1 It is well established that conventional B cells and T cells are anergized when an antigen is constantly present 2 Conversely, intermittent presence of an antigen (or epitope) promotes a persistent immune response that is similar to that seen in vaccination and vaccine recall 1 1. Schaeverbeke et al. Rheumatology 2015; [Epub ahead of print]; 2. Pradeu et al. Nat Rev Immunol 2013;13:764 9
17 Foundation of the Immune Prime-Boost Response
18 Measuring High Order Structure (HOS) of Biologics Antibody Array Enzyme-Linked Immunosorbent Assay (ELISA) The 3D conformation of a biologic protein is an important factor in its function 1,2 However it can often be difficult to define precisely using current physiochemical analytical technology 1,2 Antibody-array technology was developed to characterize HOS of mabs: 2 Measures epitope exposure and compares conformational status of biosimilar to reference product Antibody arrays can detect subtle changes not detected by any other analytical technologies 2 More than 30 polyclonal antibodies cover an entire mab Thereby measuring its surface-epitope distribution systematically and sensitively 2 1. CBER/CDER. Guidance for Industry Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Feb 2012; 2. Wang et al. BioProcess International 2014;12:32 7
19 HOS, Epitope Exposure and Immunogenicity Potential Color Change (OD 450mm) HOS Comparability of Humira and Biosimilar mabs in the Constant Region Humira Batches Biosimilar Batches Polyclonal Antibody 2/3 batches of biosimilar adalimumab indicated polyclonal increased surface-epitope exposure across all regions covered by the antibody array 1 Ab-array technology should provide a unique measurement of biosimilar mab HOS comparability and detect conformational impurity 1 HOS, high order structure 1. Wang et al. BioProcess International 2014;12:32 7
20 Induction of the Immune Response According to the Discontinuation Theory Persistent presence of an antigen induces an initial immune response followed by tolerance 1 It is well established that conventional B cells and T cells are anergized when an antigen is constantly present 2 Transition study Reference drug Biosimilar Interchangeability Substitution study (single (multiple switch) switches) Reference drug Conversely, intermittent presence of an antigen (or epitope) promotes a persistent immune response that is similar to that seen in vaccination and vaccine recall 1 Biosimilar 1. Schaeverbeke et al. Rheumatology 2015 [Epub ahead of print]; 2. Pradeu et al. Nat Rev Immunol 2013;13:764 9
21 Switching Study Design for Biosimilars and Their Reference Products 1 3 Design Randomized, controlled trials Should include at least two switches Should include appropriate control groups Size and duration Duration should be sufficient to demonstrate equivalent efficacy and to detect pre-defined safety issues or loss of efficacy Immunogenicity should always be assessed, as it can cause serious adverse events as well as drug neutralization and loss of efficacy Washout periods should be considered, particularly if there is no adequate control groups Study size should be properly calculated based on effect size and margin, calculated withdrawal rates and chosen statistical power Population For chronic diseases, should both new patients and stable treated patients be studied? Should switching studies be conducted in the most sensitive population(s)? How will interchangeability extrapolation be required/assessed/approved? 1. Lu et al. Drug Design 2013,3:1 6; 2. Endrenyi et al. Statist Med 2013;32: ; 3. Chow et al. Statist Med 2013;32:
22 Overview Introduction and Definitions Analytical Considerations Clinical Considerations The Immunogenicity Switching Challenge Clinical Evidence on Non-Medical Switching: A Review Pharmacovigilance and Patient Management In a World With Multiple Biosimilars Conclusions
23 Patents with IBD: Patients with Crohn s disease: Switching study from Remicade to Humira SWITCH trial 1 Dose optimization or treatment interruption Switch to ADA (n=36) Continue on IFX (n=37) 47% 16% p=0.003 Treatment interruption 28% 2% p<0.01 Conclusions from the SWITCH trial Adherence to the first anti-tnf is recommended 1 Important for IBD, as there are a limited number of approved biologics for these diseases 1 a Patients switched between anti-tnfs because of a lack of efficacy or because of intolerance ADA, adalimumab; IBD, inflammatory bowel disease; IFX, inflixumab 1. Van Assche et al. Gut 2012;61:229 34
24 Impact of NMS across anti-tnfs on patient outcomes: a retrospective study 1 Number of office or clinic visits per patient Initial anti-tnf (NMS cohort, N=158; control cohort, N=4804) ADA: 37.3%; 35.7% ETN: 37.3%; 51.2% IFX: 12.7%; 10.9% Office or clinic visits during follow-up a 3.1 a 1.1 a 1,5 0,5 NMS 30-Day Follow-Up 90-Day Follow-Up 1-Year Follow-Up Controls CZP: 2.5%; 0.9% GOL: 10.1%; 1.4% 5,8 % of patients Author conclusions Side effect or lack of efficacy leading to treatment adjustment during follow-up b,c 36 b NMS Cost-related switching in medically stable patients may have unintended consequences 1 63 b 30-Day Follow-Up 90-Day Follow-Up 1-Year Follow-Up 4 9 Controls Rubin et al. ECCO 2015, Barcelona, P354; Data source: Humedica EMR database ( ): Integrates EMR data from a network of >20 provider organizations treating 30 million patients across 38 US states with broad geographic representation a p<0.001 for NMS vs controls (t test and multivariate regression); b p<0.001 for NMS vs controls (chi square test and multivariate regression); c p<0.001 for NMS vs controls (chi square test), p<0.01 (multivariate regression) Patients with autoimmune diseases: rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn s disease, and ulcerative colitis
25 Review of switching across reference product and biosimilar epoetins, growth hormones and G-CSFs Switching types included in the review Review of 58 clinical trials and 12,039 patients who were switched 1 Switching across reference products Switching between reference products and biosimilars Limited clinical data that studied the effects of switching/transitioning of biologics 1 Most clinical trials not designed to identify switching-related AEs 1 Adequate substantive data and adequate post-marketing surveillance are required 1 Currently, no indication that switching/transitioning impacts on safety and efficacy 1. Ebbers et al. Expert Opin Biol Ther 2012;12: AEs, adverse events
26 What is the Evidence for Switching From Originator to Biosimilar Monoclonal Antibodies? Compare vs. Continued Ref. Product Switch x1 or Alternating Sample Size of switched cohort (n) Duration after switch Sieczkowska J et al 1 IBD Smits L. et.al. 2 IBD Kolar M. et.al. 3 IBD Díaz Hernández 4 L, et al. IBD None Single Switch 32 8 mos (range 2-11) None Single Switch wks None Single Switch wks None Single Switch 72 6 mos Fiorino G. et.al. 5 IBD Park W. et.al. 8 Ank. Spon. Yoo DH et.al. 9 Rheum. Arth. Bettey et al. 6 IBD Gesce et al. 7 IBD No: Compare vs new /re-starts* Single Switch 97 6 mos No: Compare vs biosimilar Single switch wks No: Compare vs biosimilar Single switch wks Yes Single switch 143 Up to 16 weeks No : compare vs biosimilar Observational 1. Sieczkowska J, et al. Advanced access pub JCC DOI: /ecco-jcc/jjv 2. Smits L, et al. ECCO Abstr DOP Kolar M, et al. ECCO Abstr DOP Díaz Hernández L, et al. ECCO Abstr P Fiorino G, et.al. DDW 2016 Oral Pres Abstr 439 (* New /re-starts include bio-naïve or previously TNFi exposed pts) 6. Bettey et al. ECCO 2016, DOP Gesce et al. ECCO 2016, DOP028 Single switch No direct switch (estimate ) 30 wks RCT Extensions 8. Park W, et al. Ann Rheum Dis 2016;0:1 9. doi: /annrheumdis Yoo DH, et al. Ann Rheum Dis 2016;0:1 9. doi: /annrheumdis
27 What is the evidence for switching from reference product to biosimilar mabs? Increasing evidence Heterogeneous designs Increasing outgoing evidence on switching among reference products and biosimilars on several indications, including rheumatic diseases 1 9 Study designs vary widely Randomized, active-controlled design, single-switch studies, open-label studies without a control arm, retrospective analysis, small cohorts 1 9 Data generation need There is an evident need to generate robust data on switches and interchangeability mabs, monoclonal antibodies 1. Sokka et al, EULAR 2015, Ann Rheum Dis 2015;74(Suppl. 2): 717; 2. Jarzebicka et al, 10th Congress of ECCO, Feb 2015, P Yoon Suk et al, 10th Congress of ECCO, Feb 2015, P Gesce et al. 11th Congress of ECCO, March , DOP Gesce et al. JCC 2016, Bettey et al. 11th Congress of ECCO, March , DOP029; 7. Fiorino et al. 11th Congress of ECCO, March , P544; 8. Strober B, et al. 74th AAD meeting, March , Abstract 2957; 9. Gooderham M, et al. 74th AAD meeting, March , Abstract 2961
28 Limitations of the evidence for switching from reference product to biosimilar mabs Data mostly comes from abstracts, posters and/or oral presentations from medical/scientific congresses 1 7 What do the data provide? Cohorts may provide clinically relevant important information, particularly on cumulative experience with the use of biosimilars in real life, including limited switching/transitioning data from the reference product to its biosimilar Potential limitations Number of therapy switches; open label, retrospective design, highly heterogeneous patient populations 1 7 Interpret with caution Available data may not represent final results We await final data from these cohorts and from well-designed studies 1. Sokka et al, EULAR 2015, Ann Rheum Dis 2015;74(Suppl. 2): 717; 2. Jarzebicka et al, 10th Congress of ECCO, Feb 2015, P Yoon Suk et al, 10th Congress of ECCO, Feb 2015, P Gesce et al. 11th Congress of ECCO, March , DOP Gesce et al. JCC 2016, Bettey et al. 11th Congress of ECCO, March , DOP029; 7. Fiorino et al. 11th Congress of ECCO, March , P544
29 Overview Introduction and Definitions Analytical Considerations Clinical Considerations The Immunogenicity Switching Challenge Clinical Evidence on Non-Medical Switching: A review Pharmacovigilance and Patient Management In a World With Multiple Biosimilars Conclusions
30 Reference product biologics today Uniquely identified and differ in structure 1 7 Have different mechanisms of action 7 Undergo the same full clinical development pathways required for regulatory approval 8 1. Humira SPC, November 2015, 2. Enbrel SPC, December 2015, 3. Remicade SPC, October 2015, 4. Cimzia SPC, December 2015, 5. Simponi SPC, May 2015, 6. Orencia SPC, December 2015, 7. Timlin H, et al. Expert Opin Biol Ther 2014;14: ; 8. EMA. Clinical trials in human medicine. Available at:
31 Looking towards the future: number of biologics in inflammatory/rheumatic disease will increase substantially The Present Future Established Current reference products + + new reference >36 biosimilars products 1 (new MoA) >36 biosimilars 1 The Market Will Be Complex 1. Dörner T, Kay J. Nat Rev Rheumatol 2015;11:713 24
32 Many New Biosimilar Entrants Present a Potential Complex Multi-Switch Scenario Reference product One biosimilar Two biosimilars Four biosimilars
33 Switching Between Several Biologics A biological product may not be evaluated against more than 1 reference product. 1 If A=B and A=C, does B=C follow? Reference Product A Biosimilar B Comparability studies are performed between a biosimilar and its reference product, but studies between one biosimilar and another are not done; two separate biosimilars may have been compared to the same reference but not between themselves. 2 A C B Biosimilar C, D, Thus, switching between biosimilars is not desirable and there needs to be some way of distinguishing between one SBP and another and between the reference product FDA Biologics Price Competition and Innovation Act of 2009, HR 3590: ; 2. 56th Consultation on INN for Pharmaceutical Substances, Geneva: WHO, 2013, INN working document
34 Non-medical Switching, Pharmacovigilance and Patient Management 1,2 Post-marketing surveillance of the new and complex emerging biologics market is critical NMS practice may increase the risk of misattribution of AEs, especially if the onset of the adverse reaction is delayed To avoid misattribution of adverse reactions, physician s and patient s awareness of the drug prescribed to the patient should be maximized 1. Vermeer NS et al. Expert Opin Drug Saf 2015;14:63 72; 2. Casadevall N et al. New Engl J Med 2002;346:469 75
35 Overview Introduction and Definitions Analytical Considerations Clinical Considerations The Immunogenicity Switching Challenge Clinical Evidence on Non-Medical Switching: A Review Pharmacovigilance and Patient Management In a World With Multiple Biosimilars Conclusions
36 Conclusions Reference product biologics and their biosimilars are very important treatment options for multiple diseases and have the potential to expand the possibilities for our patients The prescribing doctor needs to be in control of what their patients are receiving to improve the chances for an effective pharmacovigilance NMS between different biologics and even between versions thereof is an emerging field and highlights a need for further study Pharmacovigilance is critical; it may enable adverse effects or any other possible drug-related problems in clinical practice to be: DETECTED ASSESSED UNDERSTOOD PREVENTED
37 Obrigado! Gracias! Thank you!
Interchangeability and Substitution for Biological Medicinal Products Regulatory aspects
Interchangeability and Substitution for Biological Medicinal Products Regulatory aspects Keith Watson, PhD 12th ALIMS Symposium, Kragujevac, 28.10.2016. ADSBIO160162 Guiding Principle Access to safe and
More informationWhy even have this talk? Disclosures. What will biosimilars mean for us? Annual Revenue Due to Adalimumab. Biosimilars 2017: What We Need to Know
Biosimilars 2017: What We Need to Know Why even have this talk? Miguel Regueiro, M.D. Professor of Medicine IBD Clinical Medical Director Senior Medical Lead, Specialty Medical Homes University of Pittsburgh
More informationThe Future Role of Biosimilars: An Unknown Frontier in IBD Treatment
The Future Role of Biosimilars: An Unknown Frontier in IBD Treatment Miguel Regueiro, MD, FACG Professor of Medicine Medical Director, IBD Center Senior Medical Lead, Specialty Homes University of Pittsburgh
More informationOvercoming Challenges in the Emerging Biosimilar Landscape
Overcoming Challenges in the Emerging Biosimilar Landscape Steven R. Feldman, M.D., Ph.D. Wake Forest University School of Medicine Winston Salem, North Carolina, USA Objectives Identify the safety and
More informationThis presentation was developed by the Government & Industry Affairs Committee of the Crohn s & Colitis Foundation of America
This presentation was developed by the Government & Industry Affairs Committee of the Crohn s & Colitis Foundation of America The development of this presentation was supported in 2016 by a sponsorship
More informationThijs J Giezen, PharmD, MSc, PhD The Netherlands
Thijs J Giezen, PharmD, MSc, PhD The Netherlands Hospital Pharmacist, Foundation Pharmacy for Hospitals in Haarlem, The Netherlands Member of the Biosimilar Medicinal Product Working Party of European
More informationTOP PAPERS FROM 2016: IBD & BIOSIMILARS CYNTHIA SEOW MBBS(HONS), MSC, FRACP UNIVERSITY OF CALGARY CDDW, BANFF, AB MARCH 5, 2017
TOP PAPERS FROM 2016: IBD & BIOSIMILARS CYNTHIA SEOW MBBS(HONS), MSC, FRACP UNIVERSITY OF CALGARY CDDW, BANFF, AB MARCH 5, 2017 FINANCIAL INTEREST DISCLOSURE (OVER THE PAST 24 MONTHS) Speaker: Janssen,
More informationBiosimilars Scientific and Regulatory Considerations
Biosimilars Scientific and Regulatory Considerations Gustavo Grampp Regulatory Policy Director, Amgen Presented at Maryland Pharmacists Association meeting January 31, 2016 Program objectives 1. Review
More informationPolicy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs)
Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs) Geneva, April 2016 Appropriate use of biotherapeutics including SBPs - SBPs, also known as biosimilars, are developed to
More informationBiosimilars 101: How similar are they?
Biosimilars 101: How similar are they? Matthew Marston, Pharm.D., BCPS, BCOP Senior Manager of Clinical Pharmacy Services Miller Drug, LLC Outline Describe the approval and manufacturing process of biologics
More informationThe value of Immunogenecity. Gloria Vásquez Professor
The value of Immunogenecity Gloria Vásquez Professor Conflictos de interés en los últimos 5 años He participado en actividades académicas y asesorías: Abbvie, Pfizer, BMS, Novartis, Glaxo, y Roche He recibido
More informationThe evidence for switching stable patients to Inflectra
The evidence for switching stable patients to Inflectra Professor Silvio Danese Symposium co-chair Date of preparation: March 2017 PP-IFA-GLB-0551 Disclosures Silvio Danese has served as speaker, consultant
More informationAndrew Nesbitt, PhD. Disclaimer 10/10/2014. Determining the Immunogenicity of Biologics: a Tricky Problem. Employee of UCB ן
Determining the Immunogenicity of Biologics: a Tricky Problem Andrew Nesbitt, PhD UCB Director Cimzia PST Disclaimer 2 Employee of UCB The theories expressed in this presentation are the views of the speaker
More informationBiosimilars today or tomorrow?
Oxford Inflammatory Bowel Disease MasterClass Biosimilars today or tomorrow? Dr Vipul Jairath Bsc DPhil MRCP NIHR Clinical Lecturer Translational Gastroenterology Unit University of Oxford John Radcliffe
More informationBiosimilars Market Update
Biosimilars Market Update Panel: Matthew Brougham Consultant Economist, Brougham Consulting Inc Mark Jackson Consultant Pharmacist, TELUS Health Dr. Ed Keystone Professor of Medicine, University of Toronto
More informationLondon Medicines Evaluation Network Review
London Medicines Evaluation Network Review Answers to commonly asked questions about biosimilar versions of infliximab February 2015 (revised April 2015) Authored by Nicola Hooker (Nicola.Hooker@gstt.nhs.uk)
More informationA Physician s consideration towards Biosimilars. João Eurico Fonseca
A Physician s consideration towards Biosimilars João Eurico Fonseca Disclosure I received unrestricted research grants or acted as a speaker for Abbvie, Amgen, BMS, Celtrion, Celgene, Janssen, MSD, Novartis,
More informationBiosimilar regulation from a clinical point of view
Biosimilar regulation from a clinical point of view an update on immunogenicity and interchangeability LIS-TNFBio seminar 2018 Scandic Nidelven Hotel Trondheim 20.-21. mars Senior Advisor Project leader
More informationL ESPERIENZA DEL REUMATOLOGO. Prof. Roberto Giacomelli Direttore Cattedra e scuola di specializzazione Reumatologia L Aquila
L ESPERIENZA DEL REUMATOLOGO Prof. Roberto Giacomelli Direttore Cattedra e scuola di specializzazione Reumatologia L Aquila INTRODUCTION Biosimilars, biopharmaceuticals that have been assessed by regulatory
More informationImmunogenicity of biotherapeutics; an introduction
Immunogenicity of biotherapeutics; an introduction PKUK 6 th November 2014 Hishani Kirby PhD, UCB Contents Background The importance of understanding Anti drug antibodies (ADAs) The immune response Factors
More informationBiosimilars an update
Biosimilars an update Darren Roberts Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Clinical pharmacology and toxicology, St Vincent s Hospital (Sydney) Nephrology,
More informationAMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT
AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT SUBJECT: PRESENTED BY: FOR DISTRIBUTION TO: Biosimilars Committee on Rheumatologic Care Members of the American College of Rheumatology Medical Societies
More informationSandoz Biopharmaceuticals. Sandoz Biosimilars. From concept to reality
Sandoz Biopharmaceuticals Sandoz Biosimilars From concept to reality 2 SANDOZ BIOPHARMACEUTICALS The basics of biosimilars Biosimilars explained Biologic medicines are produced by a complex process involving
More informationWhat next? Manufacture the biosimilar product
What next? Manufacture the biosimilar product Design manufacturing process to match QTPP Full quality dossier required. Use state of the art technologies In accordance with relevant ICH and CHMP guidelines
More informationRE: Considerations in Demonstrating Interchangeability With a Reference Product; Draft Guidance for Industry; Availability (FDA 2017 D )
May 19, 2017 Scott Gottlieb, MD Commissioner U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 RE: Considerations in Demonstrating Interchangeability With a Reference
More informationNaming, tracing, switching and other safety issues after 10 years learning
Naming, tracing, switching and other safety issues after 10 years learning Prof. Dr. Irene Krämer, Department of Pharmacy Johannes Gutenberg-University Medical Center, Mainz (Germany) Disclosures Speaker
More informationACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm
ACG Public Forum Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD Monday, 12:45 pm 2:15 pm Biosimilars for IBD: What the Gastroenterologist Needs to Know Tara Altepeter, MD Clinical Team
More informationBiosimilar mabs Clinical issues Regulatory perspective
Biosimilar mabs Clinical issues Regulatory perspective EMEA Workshop on Biosimilar Monoclonal Antibodies, MD BMWP Chairman European Medicines Agency (EMEA), UK Paul-Ehrlich-Institut, Germany Mechanisms
More informationACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm
ACG Public Forum Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD Monday, 12:45 pm 2:15 pm ACG 2017: FDA-EMA workshop on biosimilars Joachim Musaus EMA Product Lead Gastroenterology Human
More informationProfessor Tore Kristian Kvien, MD, PhD, Norway
GaBI Scientific Meetings 10 October 2018, Le Meridien Dubai, United Arab Emirates 2nd MENA Stakeholder Meeting on Regulatory Approval, Clinical Settings, Interchangeability and Pharmacovigilance of Biosimilars
More informationSwitching from Reference Biologic Medicines to Biosimilars
Scientific Affairs Switching from Reference Biologic Medicines to Biosimilars Hillel P Cohen, PhD Academy of Managed Care Pharmacy - Webinar July 12, 2018 Biosimilars are approved biologics that have been
More informationBiosimilar Monoclonal- a reality
Biosimilar Monoclonal- a reality 2 nd MENA Regulatory Conference on Bioequivalence, Biowaivers, BIOANALYSIS, DISSOLUTION AND BIOSIMILARS Jordan DATE September 15-17, 2015 PRESENTED BY Rodeina Challand
More informationBiosimilars Scientific Challenges and Implications
Biosimilars Scientific Challenges and Implications Professor Paul Declerck Laboratory for Therapeutic and Diagnostic Antibodies paul.declerck@pharm.kuleuven.be Biological medicinal product A well-defined
More informationClosed Workshop on biosimilar monoclonal antibodies and immunogenicity of monoclonal antibodies October 2011 Dr Christian K Schneider, MD
Draft guideline on biosimilar monoclonal antibodies Closed Workshop on biosimilar monoclonal antibodies and immunogenicity of monoclonal antibodies October 2011 Dr Christian K Schneider, MD CHMP Biosimilar
More informationOptimizing the Development of Biosimilars Using PK/PD: Recent Scientific and Regulatory Advances
Optimizing the Development of Biosimilars Using PK/PD: Recent Scientific and Regulatory Advances Jian Wang, MD, PhD Chief, Clinical Evaluation Division Biologics and Genetic Therapies Directorate Health
More informationfact sheet 3 Introduction to Biosimilars & Regulatory Requirements
3 fact sheet 3 Introduction to Biosimilars & Regulatory Requirements International Alliance of Patients Organizations CAN Mezzanine 49-51 East Road London N1 6AH United Kingdom International Federation
More informationACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm
ACG Public Forum Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD Monday, 12:45 pm 2:15 pm Overview of the Regulatory Pathway and FDA s Guidance for the Development and Approval of Biosimilar
More informationFDA Public Hearing: Approval Pathway for Biosimilar. Products. November 2-3, 2010
FDA Public Hearing: Approval Pathway for Biosimilar and Interchangeable Biological Products November 2-3, 2010 1 The Biotechnology Industry Organization Over 1,100 members, including biotechnology companies,
More informationBIOSIMILARS: How Do They Affect Patient Care and Safety?
BIOSIMILARS: How Do They Affect Patient Care and Safety? Josie Garnoc, MSN, RN, CRNI, OCN Director of Nursing, Beaumont Hospital-Grosse Pointe Grosse Pointe, Michigan Disclosure Statement Nothing to Disclose
More informationBiosimilar Development Clinical Investigator Considerations
Biosimilar Development Clinical Investigator Considerations June 2011 www.ppdi.com Biosimilar products are not new in the pharmaceutical industry. However, the pending expiration of numerous therapeutic
More informationImmunogenicity: Impact on the Design of Clinical Trials for Biosimilars
Immunogenicity: Impact on the Design of Clinical Trials for Biosimilars Alexander Berghout, M.D., Ph.D. Head Global Clinical Research and Development Sandoz Biopharmaceuticals BMWP/BWP Workshop on Immunogenicity
More informationBIOLOGIC AND BIOSIMILAR MEDICATIONS
BIOLOGIC AND BIOSIMILAR MEDICATIONS IN THE TREATMENT OF IBD crohnsandcolitis.ca BIOLOGIC AND BIOSIMILAR MEDICATIONS IN THE TREATMENT OF IBD Crohn s disease and ulcerative colitis are the two main forms
More informationBiological and Functional Analysis of
Biological and Functional Analysis of Biosimilar TNFαDrugs Daniel N Galbraith Chief Scientific Officer, BioOutsource Ltd. Reliable quality, on time, every time Drug Characterisation Activities Functional
More informationNDA Advisory Services Ltd
Declaration of Interest statement: Paul Chamberlain has received Consulting fees from different companies in respect of strategic and operational advice relating to biopharmaceutical development; he is
More informationThe importance of interchangeability in the procurement of medications: Biosimilar case
The importance of interchangeability in the procurement of medications: Biosimilar case ALIMS Congres, Kragujevac, November 6, 2015 Prof. Borut Štrukelj, PhD Brief CV Current position: professor, Pharmaceutical
More informationClinical Immunogenicity and the Biosimilar paradigm
Clinical Immunogenicity and the Biosimilar paradigm Dr Syed Numan 05 March 2015 Guiding Principles Access to safe and effective medicines is important to patients, to those who care for them and to AbbVie.
More informationProfessor Aws Alshamsan, BPharm, RPh, PhD, Saudi Arabia
GaBI Scientific Meetings First GCC Stakeholder Meeting on Approval Process, Interchangeability/Substitution and Safety of Biosimilars 20 November 2017, Holiday Inn Izdihar Riyadh, Saudi Arabia Professor
More informationBIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD. crohnsandcolitis.ca
BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD crohnsandcolitis.ca BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD INFLAMMATION AND IMMUNITY IN CROHN S AND COLITIS Inflammation is the body s normal and natural
More informationProfessor Ahmed H Al-jedai, PharmD, MBA, BCPS, FCCP, FAST, Saudi Arabia
GaBI Scientific Meetings First GCC Stakeholder Meeting on Approval Process, Interchangeability/Substitution and Safety of Biosimilars 20 November 2017, Holiday Inn Izdihar Riyadh, Saudi Arabia Professor
More informationPharmacovigilance for biotherapeutics: Partnering for patient safety
International Federation of Pharmaceutical Manufacturers & Associations Pharmacovigilance for biotherapeutics: Partnering for patient safety Fermin Ruiz de Erenchun IFPMA Biotherapeutics Group Chair (F.
More informationL ESPERIENZA ITALIANA
L ESPERIENZA ITALIANA Alessandro Armuzzi IBD Unit Presidio Columbus Fondazione Policlinico Gemelli Università Cattolica - Roma Disclosures Consultant: AbbVie, Biogen, Celltrion, Ferring, Hospira, Janssen,
More informationAn innovative solution to the rising cost of drug-benefit plans
An innovative solution to the rising cost of drug-benefit plans INTRODUCED BY Biologics Savings Partnership CANADIAN DRUG PLAN SPENDING ON SPECIALTY DRUGS, INCLUDING BIOLOGICS, CONTINUES TO INCREASE 1,2
More informationUNRAVELLING THE MYSTERY BETWEEN STRUCTURE AND SUSTAINED CLINICAL OUTCOMES
UNRAVELLING THE MYSTERY BETWEEN STRUCTURE AND SUSTAINED CLINICAL OUTCOMES This symposium took place on 9 th June 2016 as a part of the European League Against Rheumatism (EULAR) Congress 2016 in London,
More informationBIOSIMILARS AND SWITCHING: WHAT IS YOUR PERSPECTIVE?
BIOSIMILARS AND SWITCHING: WHAT IS YOUR PERSPECTIVE? This satellite symposium took place on 16 th June 2017 as a part of the European League Against Rheumatism (EULAR) Congress in Madrid, Spain Chairperson
More informationUpdate on the new immunogenicity guideline in the EU
Update on the new immunogenicity guideline in the EU draft 2016 EBF, Lisbon 27 th September 2016 Venke Skibeli, Senior Scientist, PhD Norwegian Medicines Agency, Member of the CHMP - BMWP, EMA, London
More informationImportant Facts. Health Care Professionals Should Know About Biosimilars
Important Facts Health Care Professionals Should Know About Biosimilars Biosimilars: Defining Characteristics Biosimilars are highly similar versions of reference biologics, with no clinically meaningful
More informationSurvey 1 - Rheumatoid Arthritis (RA) Patients perception on originator biologics and biosimilars
SUPPLEMENTAL MATERIAL - Perception of originator biologics and biosimilars: a survey amongst Belgian rheumatoid arthritis patients and rheumatologists BioDrugs Eline van Overbeeke 1, Birgit De Beleyr,
More informationRegulatory Issues and Drug Product Approval for Biopharmaceuticals
Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop
More informationImplications for Preclinical and Clinical Programs. Novartis Pharmaceuticals Oncology Business Unit June 2, 2011
EU Biosimilarityi il it Guidance Implications for Preclinical and Clinical Programs Shefali Kakar Novartis Pharmaceuticals Oncology Business Unit June 2, 2011 Biologics are more complex than small molecules
More informationCancer Vanguard. An introduction to Biosimilars
An introduction to Biosimilars Cancer Vanguard Overview The Cancer Vanguard comprises RM Partners UCLH Cancer Collaboration Greater Manchester Cancer Vanguard Innovation These three local delivery systems
More informationOverview of Biologics (Including Biosimilars)
Overview of Biologics (Including Biosimilars) 2015 Sandoz Inc. All Rights Reserved. The material contained in this slide deck may not be altered or reproduced without express written consent from Sandoz
More informationInterchangeability: What is Next? Analysis of the concept & of the FDA Draft Guidance
Interchangeability: What is Next? Analysis of the concept & of the FDA Draft Guidance Hillel Cohen, Executive Director of Scientific Affairs Leading on Biosimilars: The 2017 AAM Biosimilars Council Conference
More informationFIP STATEMENT OF POLICY Pharmacist's authority in pharmaceutical product selection: therapeutic interchange and substitution
Pharmacist's authority in pharmaceutical product selection: therapeutic interchange and substitution Purpose: The purpose of this document is to provide a set of recommendations on therapeutic interchange
More informationASBM Biosimilars. Canada Prescribers and Biosimilars October, Kevin Olson, CEO Industry Standard Research
ASBM Biosimilars Canada Prescribers and Biosimilars October, 2017 Kevin Olson, CEO Industry Standard Research KevinO@ISRreports.com Table of contents Page 3 Methodology 5 Sample Characteristics 6 Executive
More informationTHE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS
THE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS What all developers need to know Alicia Baker Director, Global Regulatory Affairs Strategy, Covance John Carlsen, MHA Vice President,
More informationInmunogenicidad de Biológicos/Biosimilares
Inmunogenicidad de Biológicos/Biosimilares Gilberto Castañeda Hernández Departamento de Farmacología Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional Ciudad de México
More informationWhat Is a Biosimilar?
Learning Objectives Compare and contrast biosimilars to their reference product and generic therapies in terms of structure, manufacturing, regulatory pathway, and clinical properties Evaluate evolving
More informationThe Future has Arrived: Biosimilars
The Future has Arrived: Biosimilars Overview of the Regulatory Framework and FDA s Guidance for the Development and Approval of Biosimilar and Interchangeable Products in the US Sue Lim, M.D., Director
More informationRasha Sayed Salama, MD, PhD, UAE
GaBI Scientific Meetings 10 October 2018, Le Meridien Dubai, United Arab Emirates 2nd MENA Stakeholder Meeting on Regulatory Approval, Clinical Settings, Interchangeability and Pharmacovigilance of Biosimilars
More informationImportant Considerations for the Introduction of Biosimilars in the U.S. Frank A. Scappaticci, MD, PhD
Important Considerations for the Introduction of Biosimilars in the U.S. Frank A. Scappaticci, MD, PhD Global Clinical Science Leader Genentech, Inc. / F. Hoffmann-La Roche Ltd. November 7, 2013 Outline
More informationREFERENCE CODE GDHC347DFR PUBLICAT ION DATE FEBRUARY 2014 SIMPONI (ULCERATIVE COLITIS) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC347DFR PUBLICAT ION DATE FEBRUARY 2014 SIMPONI (ULCERATIVE COLITIS) - Executive Summary Table below provides a summary of the key metrics for Simponi in the 10MM Ulcerative Colitis (UC)
More informationVladimir Hanes, MD, USA
GaBI Educational Workshops 20 January 2015, Sheraton Maria Isabel Hotel & Towers, Mexico City, Mexico Vladimir Hanes, MD, USA Medical Director, Oncology Global Biosimilars Development, Amgen Inc GaBI Educational
More informationThe Future has Arrived: Biosimilars
The Future has Arrived: Biosimilars Overview of the Regulatory Framework and FDA s Guidance for the Development and Approval of Biosimilar and Interchangeable Products in the US Sue Lim, M.D., Director
More informationMedicines Agency EMA & Biosimilar update: Trends from marketing authorisation applications, scientific advice procedures and policies
EMA & Biosimilar update: Trends from marketing authorisation applications, scientific advice procedures and policies Presented by: Peter Richardson Head of Quality Office Specialised Scientific Disciplines
More informationImmunogenicity. How to deal with? Nathalie Macé Sanofi, Biomarkers & Biological analyses Unit
Immunogenicity How to deal with? Nathalie Macé Sanofi, Biomarkers & Biological analyses Unit Club Phase I, 22 March 2016 1 Outline Introduction to immunogenicity Analytical challenges for immunogenicity
More informationBIOSIMILARS OF PROTEIN BASED DRUGS: CURRENT STATUS AND FUTURE DIRECTIONS
BIOSIMILARS OF PROTEIN BASED DRUGS: CURRENT STATUS AND FUTURE DIRECTIONS George Dranitsaris B.Pharm. PhD Consultant in Health Economics and Biostatistics What is a Biosimilar? Protein based drugs are made
More informationBiosimilars. Their regulatory status and their use
Biosimilars Their regulatory status and their use Bruno Flamion, MD, PhD Professor of Physiology & Pharmacology, University of Namur, Belgium Past Chair of the European Medicines Agency (EMA) Scientific
More informationSol Ruiz, PhD, Spain
GaBI Scientific Meetings ROUNDTABLE ON BIOSIMILARS Pharmacovigilance, Traceability, Immunogenicity 15 November 2016, Real Academia Nacional de Farmacia, Madrid, Spain Sol Ruiz, PhD, Spain Head of Sector,
More informationAssays for Immunogenicity: Are We There Yet?
Assays for Immunogenicity: Are We There Yet? Mark Wener, MD Department of Laboratory Medicine & Rheumatology Division Department of Medicine University of Washington Seattle, WA 98195 wener@uw.edu Goals:
More informationBiosimilars Clarified
Biosimilars Clarified 1 Learning Objectives Identify the key features of biological products and biosimilars Understand the biosimilar development pathway and clinical trials that assess biosimilarity
More informationBiosimilars China Guideline. Dr Dr Michel Mikhail
Biosimilars China Guideline Dr Dr Michel Mikhail 1 Contents Regulatory context of biologicals in China Decree 28 issued by SFDA October 2007 Proposed biosimilars guideline 10/29/14 Reference drugs to use
More informationPaving the way for Non-Clinical Bioanalytical Partnerships Louise Angell
Paving the way for Non-Clinical Bioanalytical Partnerships Louise Angell Content Overview of non-clinical immunogenicity testing for biologics Regulatory guidance Bioanalytical considerations Risk based
More informationDivision of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852
Reference No.: FDAA10017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 VIA WEB SUBJECT: Approval Pathway for Biosimilar and Interchangeable
More informationPractical challenges in the CMC development of biosimilars. Simon Hotchin Executive Director Regulatory Affairs Amgen Inc.
Practical challenges in the CMC development of biosimilars Simon Hotchin Executive Director Regulatory Affairs Amgen Inc. Overview Introduction Statistical methodologies in the assessment of analytical
More informationSharmila et al. International Journal of Drug Regulatory Affairs; 2017, 5(1), ISSN: Available online at
REGULATORY REQUIREMENTS OF SIMILAR BIOLOGICS FOR MARKETING AUTHORIZATION IN INDIA Available online at www.ijdra.com REVIEW ARTICLE Sharmila Reddy V*, Mounica N.V.N., Anusha S, Evangeline L, Nagabhushanam
More informationBiosimilars: Size does matter? João Eurico Fonseca
Biosimilars: Size does matter? João Eurico Fonseca Disclosure I received unrestricted research grants or acted as a speaker for Abbvie, Amgen, BMS, Celtrion, Celgene, Janssen, MSD, Novartis, Novo Nordisk,
More information5 key characteristics
Biosimilars 5 key characteristics Biologics are medicinal products derived from living organisms. 1 Their use has impacted the treatment of a variety of diseases. 1 Patents for many biologics will soon
More informationTechnical Challenges in the Development of Biosimilars. E. Morrey Atkinson, PhD Interphex May 1, 2012
Technical Challenges in the Development of Biosimilars E. Morrey Atkinson, PhD Interphex May 1, 2012 FDA Guidance on Biosimilarity Guidance for Industry: Scientific Consideration in Demonstrating Biosimilarity
More informationREFERENCE CODE GDHC354DFR PUBLICAT ION DATE FEBRUARY 2014 UCERIS (ULCERATIVE COLITIS) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC354DFR PUBLICAT ION DATE FEBRUARY 2014 UCERIS (ULCERATIVE COLITIS) - Executive Summary Table below provides a summary of the key metrics for Uceris in the 10MM Ulcerative Colitis (UC)
More informationBiosimilar Drug Landscape
Biosimilar Drug Landscape Biosimilars: Incorporating Use into Practice and Clinical Implications for Pharmacists Jessica Farrell, PharmD. Clinical Pharmacist- The Center for Rheumatology, LLC Associate
More informationTHE EVOLVING BIOSIMILAR LANDSCAPE: APPROVAL OF THE FIRST ETANERCEPT BIOSIMILAR IN EUROPE AN INTERVIEW WITH EMILIO MARTÍN-MOLA
THE EVOLVING BIOSIMILAR LANDSCAPE: APPROVAL OF THE FIRST ETANERCEPT BIOSIMILAR IN EUROPE AN INTERVIEW WITH EMILIO MARTÍN-MOLA *Caroline Charles Scilink Medical Writing, Biarritz, France. *Correspondence
More informationSwitching from Reference to Biosimilar Products: An Overview of the European Approach and Real-World Experience So Far
Switching from Reference to Biosimilar Products: An Overview of the European Approach and Real-World Experience So Far Authors: *Anna La Noce, 1 Marcin Ernst 2 1. General Medicine, Syneos Health, Saronno,
More informationEffect of Naming on Competition and Innovation. Mark McCamish, MD, PhD Global Head Biopharmaceutical Development Washington, DC 10 December 2013
Effect of Naming on Competition and Innovation Mark McCamish, MD, PhD Global Head Biopharmaceutical Development Washington, DC 10 December 2013 1 FTC Biosimilars Workshop on Naming Proposals and Impact
More informationBaek, Kyung-min. Recombinant Protein Products Division. Ministry of Food and Drug Safety
Baek, Kyung-min Recombinant Protein Products Division Ministry of Food and Drug Safety About Ministry of Food and Drug Safety Regulation for Biosimilar Principle of Biosimilar Approach Status of Biosimilar
More informationThe Evolving Role Of Prescription Benefit Managers
The Evolving Role Of Prescription Benefit Managers Steve Miller, MD Senior Vice President & Chief Medical Officer November 1, 2016 1 Prescription drugs: A growing share of U.S. healthcare spend Net spending
More informationREFERENCE CODE GDHC348DFR PUBLICAT ION DATE FEBRUARY 2014 APRISO (ULCERATIVE COLITIS) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC348DFR PUBLICAT ION DATE FEBRUARY 2014 APRISO (ULCERATIVE COLITIS) - Executive Summary Table below provides a summary of the key metrics for Apriso in the 10MM Ulcerative Colitis (UC)
More informationREFERENCE CODE GDHC221CFR PUBLICATION DATE FEBRUARY 2014 ULCERATIVE COLITIS - CANADA DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC221CFR PUBLICATION DATE FEBRUARY 2014 ULCERATIVE COLITIS - CANADA DRUG FORECAST Executive Summary Sales for Ulcerative Colitis in Canada In 2012, GlobalData estimated that Canada Ulcerative
More informationThe Future of the U.S. Biosimilars Market: Development, Education, and Utilization. October 18, 2016
The Future of the U.S. Biosimilars Market: Development, Education, and Utilization October 18, 2016 ABOUT THE DUKE MARGOLIS CENTER FOR HEALTH POLICY The Duke-Robert J. Margolis, MD, Center for Health Policy,
More informationImmunogenicity Assay Strategies for Antibody-Drug Conjugates
Immunogenicity Assay Strategies for Antibody-Drug Conjugates 8th World ADC Conference, San Diego 20 Sep 2017 Seema Kumar, PhD Associate Scientific Director Global Early Development (GED) EMD Serono Research
More informationRevised Immunogenicity Guideline: Assays and methods- Presentation of the draft guideline and introduction of the topics for discussion
Revised Immunogenicity Guideline: Assays and methods- Presentation of the draft guideline and introduction of the topics for discussion Robin Thorpe & Meenu Wadhwa Revised Guideline: Differences from original
More information